AI drug-discovery picks and shovels such as Ginkgo Bioworks, 10x Genomics, Twist Bioscience and Grail are priced on a fantasy, and secondary offerings are coming. The bet that AI will solve cancers and rare diseases within months ignores how drug discovery, regulation and trial enrollment actually work. Unlike the semiconductor comparison, these businesses have not inflected, mostly burn cash, trade at 20-30x sales and need equity to fund themselves. Buyers here become their liquidity. x.com  … Show more

AI-for-science stocks show a typical pump-and-dump setup driven by Chinese and Hong Kong hedge funds, and more pumps and dumps are likely. These funds trade narratives and price in an extremely bright future, so consensus forms fast and crowded positions reverse easily. When Chinese sell-side analysts or the Chinese community on X are loud about a thesis, it is a trade to avoid. Fundamentals still look exciting, and key moving averages are the signal to re-enter long. x.com  x.com 

Biotech, including Thermo Fisher, Eli Lilly, Intellia, CRISPR, Illumina and NeoGenomics, stands to gain as AI-trade capital rotates out of infrastructure, since healthcare is the largest market AI has yet to disrupt. AI hardware is worth about $14 trillion versus $1.4 trillion for biotech, so a 2.5% rotation could, at 5x inelasticity, put $1.75 trillion of pressure on biotech. Capital isn't leaving the AI trade; the equal-weighted S&P 500 is at all-time highs. x.com  x.com 

Biotech stocks are breaking out of a five-year range because the threat from oil and interest rates was priced in years ago. Many of the most undervalued growth stocks are now in biotech, and research discovery is getting a boost from AI, making it perhaps the sector with most to gain from AI productivity. Charts support it: daily volume spikes have tended to mark major bottoms, the weekly held its quarterly averages to form a base, and the monthly shows a healthy pullback to the one-year EMA. … Show more

Fintech is investing while biotech is gambling: roughly 90% of biotechs fail versus 10% of fintechs. Most fintechs are growing 25-30% or more yet trade at record-low valuations, while biotech is already up 90% and in a bubble driven by buyout mania. x.com 

Illumina is one of the best names in a hot medtech and medical-device group, and healthcare is generally a good place to be when tech gets wrecked. x.com 

Genomics stocks appear to be benefiting from AI, with the ARK Genomic Revolution ETF clearly outpacing broader biotech. x.com 

Biotech is back. A quoted report says lab monkey prices in China have surged to about $26,000 each as the biotech boom overwhelms supply. x.com 

Genomics is likely one of the most important long-term investment themes of the next decade, as AI speeds how life's information is read, understood and edited. Picks: Illumina in sequencing; Tempus AI for AI with genomic data; CRISPR Therapeutics and Beam in gene editing; uniQure (high risk, high payoff) and BioMarin (more certain) in gene therapy; Natera and Guardant Health in diagnostics; Twist Bioscience and Thermo Fisher in tools; Vertex and Alnylam in therapeutics. x.com 

Bio-diagnostics offers the best value in the market, trading at lower price-to-sales multiples than software with low correlation to the AI trade. Its data-services businesses should become increasingly important because of AI. Tempus is the key name to understand, with smaller players including Exagen, Quanterix and GeneDx in the theme, and Caris Life Sciences just posted great results. x.com  x.com